Can automation deliver truly scalable manufacturing in CGT?
Following their recent partnership announcement with Johnson & Johnson, the Cellular Origins team unpacks the news and the implications for the industry.
26 Mar 2026
|
Gordon Wong
Automation is central to advancing CGT manufacturing, yet the sector must reconcile technical innovation with the variability and complexity of living therapies. This session explores how automation can support reproducibility, streamline quality control, and expand production capacity without compromising adaptability.
Key Takeaways:
Assess the role of automation in reproducibility, efficiency, and quality monitoring
Identify integration strategies that maintain flexibility across variable manufacturing processes
Examine how automated systems can scale therapies to meet patient demand
Compare methods for balancing innovation with operational complexity in CGT production
Evaluate automation’s contribution to sustainable, high-volume manufacturing models
Date: 26 March 2026
Session Chair
Edwin Stone (Chief Executive Officer | Cellular Origins)
Speakers
Meg Wood (Managing Director | NYBC Ventures)
John Knighton (Vice President, API Large Molecule Development | Johnson & Johnson)
Advanced Therapies Week 2027
Join the industry in San Diego | January 18-21 2027 for four days of high-impact networking, deal-making and innovation across cell and gene therapy. Bringing together 1,800+ biotech, pharma, CDMO and investment leaders, this is where scientific progress, partnering and commercialization come together.
)